<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Immunology 2002 106 200&#226;&#8364;&#8220;211 <br />  <br />  <br />  <br />  <br />    Accumulation potent cd T-cell stimulator deletion lytB gene <br />                                Escherichia coli <br />  <br />  <br />    MATTHIAS EBERL,*&quot; BORAN ALTINCICEK,{&quot; ANN-KRISTIN KOLLAS,*&quot; SILKE SANDERBRAND,{ <br />     UTE BAHR,{ ARMIN REICHENBERG,{ EWALD BECK,* DONALD FOSTER,1 JOCHEN WIESNER,{ <br /> MARTIN HINTZ{ <span id='am-32' about='obo:IMR_0200083' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-33' property="oboInOwl:hasExactSynonym" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-34' property="rdfs:label" content="AMP" datatype="xsd:string"></span><span id='am-35' property="rdfs:label" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-36' property="oboInOwl:id" content="IMR:0200083" datatype="xsd:string"></span><span id='am-37' property="oboInOwl:hasDbXref" content="KEGG:C00020" datatype="xsd:string"></span><span id='am-38' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>amp</span>; HASSAN JOMAA{ *Biochemisches Institut, Justus-Liebig-Universita&#194;&#168;t Giessen, Giessen, Germany, <br />  {Jomaa Pharmaka GmbH, Giessen, Germany, {Instrumentelle Analytische Chemie, Johann Wolfgang Goethe-Universita&#194;&#168;t <br />       Frankfurt Main, Frankfurt, Germany 1Department Cytokine Biology, Zymogenetics , Seattle, <br />                                                Washington, USA <br />  <br />  <br />  <br />  <br />                                                             SUMMARY <br />                  Activation human Vc9/Vd2 T cells pathogens depends presence small <br />                  phosphorylated non-<span id='am-5' about='obo:IMR_0001700' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-6' property="oboInOwl:id" content="IMR:0001700" datatype="xsd:string"></span><span id='am-7' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-8' property="rdfs:label" content="peptide" datatype="xsd:string"></span><span id='am-9' property="obo:IAO_0000115" content="The polypeptide that is not a gene product." datatype="xsd:string"></span>peptide</span> compounds derived 2-C-methyl-D-erythritol <br />                  4-phosphate (MEP) pathway isoprenoid biosynthesis. demonstrate                  Escherichia coli mutants deficient lytB, essential gene MEP pathway, potent <br />                  Vc9/Vd2 T-cell activator accumulates factor approximately 150 compared wild-type <br />                  E. coli. compound responsible strong immunogenicity E. coli mutant                  subsequently characterized identified small pyrophosphorylated metabolite,                  molecular mass 262 Da, derived MEP pathway. Stimulation human peripheral <br />                  blood mononuclear cells (PBMC) extracts prepared lytB-deficient E. coli <br />                  mutant led upregulation T-cell activation markers surface Vc9/Vd2 T cells                  proliferation expansion Vc9/Vd2 T cells. response dependent                  costimulatory growth factors, interleukin  -2, 15 21. Significant levels                  interferon-c (IFN-c) tumour necrosis factor (TNF  secreted presence                  2 15, presence 21, demonstrating proliferating <br />                  phosphoantigen-reactive Vc9/Vd2 T cells necessarily produce proinflammatory <br />                  cytokines. <br />  <br />  <br />  <br />  <br />                                                                                              INTRODUCTION <br />                                                                           cd T cells play crucial role immune response <br />    Received 29 October 2001; revised 16 January 2002; accepted            microbial pathogens, capable 11 February 2002. <br />                                                                           establishing chronic debilitating diseases,    Abbreviations: DOXP, 1-deoxy-<span id='am-62' about='obo:IMR_0200169' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-63' property="oboInOwl:id" content="IMR:0200169" datatype="xsd:string"></span><span id='am-64' property="oboInOwl:hasDbXref" content="KEGG:C00231" datatype="xsd:string"></span><span id='am-65' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-66' property="rdfs:label" content="D-Xylulose 5-phosphate" datatype="xsd:string"></span>D-xylulose 5-phosphate</span>; Dxr,              tuberculosis malaria.1,2 humans, activation Vc9/ <br /> 1-deoxy-D-xylulose 5-phosphate reductoisomerase; ESI, electro-            Vd2 T cells pathogenic micro-organisms depends <br /> spray ionization; FBPP, 3-formyl-1-butyl <span id='am-16' about='obo:IMR_0200280' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-17' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-18' property="oboInOwl:hasDbXref" content="KEGG:C00013" datatype="xsd:string"></span><span id='am-19' property="oboInOwl:id" content="IMR:0200280" datatype="xsd:string"></span><span id='am-20' property="rdfs:label" content="Pyrophosphate" datatype="xsd:string"></span>pyrophosphate</span>; <br />                                                                           compounds derived 2-C-methyl-D-erythritol <br /> HMB-PP, (E )-4-hydroxy-3-methyl 2-enyl pyrophosphate; <br /> IFN-c, interferon-c;  interleukin; IPP, isopentenyl pyrophos- <br />                                                                           4-phosphate (MEP)1 pathway isoprenoid biosynthesis.3,4 <br /> phate; LMW, low molecular weight;  2-C-methyl-D-erythritol;            chloroplasts algae higher plants, <br /> MEcPP, 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate; MEP,               pathway utilized bacteria,5,6 2-C-methyl-D-erythritol 4-phosphate; MS, mass spectrometry;               apicomplexan protozoa Plasmodium falciparum,7 <br /> TNF  tumour necrosis factor                                           apparently absent vertebrates.8&#226;&#8364;&#8220;11      &quot;M. Eberl, B. Altincicek -K. Kollas contributed equally         unconventional cd T-cell reactivity common metabolites work.                                                             ensures quick efficient immune response                                                                           broad range evolutionarily distant pathogens     Correspondence: Dr M. Eberl, Biochemisches Institut, <br /> Klinikum der Justus-Liebig-Universita&#194;&#168;t Giessen, Friedrichstrasse         escape classical major histocompatibility <br /> 24, D-35392 Giessen, Germany. E-mail: matthias.eberl@biochemie.           complex-restricted mechanisms.12 isopentenyl pyro- <br /> med.uni-giessen                                                        phosphate (IPP), precursor isoprenoids,  <br />  <br />                                                                     200                                  #   2002 Blackwell Science                                      potent cd T-cell activator DlytB E. coli                                     201 <br />  <br />  ligand described Vc9/Vd2 T-cell receptor          isomerase (<span id='am-67' about='obo:IMR_0200167' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-68' property="oboInOwl:id" content="IMR:0200167" datatype="xsd:string"></span><span id='am-69' property="rdfs:label" content="D-Glyceraldehyde" datatype="xsd:string"></span><span id='am-70' property="oboInOwl:hasDbXref" content="KEGG:C00577" datatype="xsd:string"></span><span id='am-71' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>D-glyceraldehyde</span>-3-phosphate-ketol-isomerase; <br /> (TCR),13&#226;&#8364;&#8220;15 natural amounts IPP bacteria           Sigma) 40 mg recombinant E. coli DOXP synthase.24 reach minimum required inducing T-cell              [2-14C]DOXP precipitated 100 mM BaCl2 activation.3 Fournie&#194;&#180; workers showed              80% ethanol, subsequently transformed mycobacterial molecule likely 3-formyl-1-butyl            [2-14C]MEP presence 25 mM <span id='am-44' about='obo:IMR_0200463' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-45' property="oboInOwl:hasDbXref" content="KEGG:C00005" datatype="xsd:string"></span><span id='am-46' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-47' property="oboInOwl:id" content="IMR:0200463" datatype="xsd:string"></span><span id='am-48' property="rdfs:label" content="NADPH" datatype="xsd:string"></span>NADPH</span> (Sigma) <br /> pyrophosphate (FBPP) approximately 1000-fold            using 300 mg recombinant E. coli DOXP reducto- <br /> active IPP;16,17 structural similarity   isomerase (Dxr).7 Samples passed porous <br /> IPP, FBPP suggested intermediate MEP        graphitized carbon column (Hypercarb; Thermo Hypersil, <br /> pathway.17  terminal steps MEP               Runcorn, UK). Finally, [2-14C]MEP purified pathway remain elucidated, 2-C-methyl-D-       MonoQ column (Amersham Pharmacia, Freiburg, <br /> erythritol 2,4-cyclopyrophosphate (MEcPP)        Germany), using 20 mM Tris&#226;&#8364;&#8220;HCl, pH 8.0, rising <br /> metabolite reaction sequence known far,           concentrations NaCl, Gynkotech HPLC device <br /> evidence FBPP natural intermediate IPP             (Gynkotech, Germering, Germany). procedure <br /> biosynthesis missing.18                                      yielded &lt;1.6 mg [2-14C]MEP activity      recently, role genes dxr, gcpE lytB     &lt;344 MBq/mmol (data shown). MEP pathway demonstrated 19&#226;&#8364;&#8220;23 constructed Escherichia coli mutant strains <br />                                                                 Metabolic 14C labelling metabolites derived utilizing exogenously provided mevalonate producing <br />                                                                 MEP pathway <br /> IPP, owing complementation plasmid                                                                 fresh overnight culture DgcpE DlytB mutants, <br /> provides yeast enzymes classical mevalonate <br />                                                                 respectively, diluted 1 : 100 2 ml medium sup- <br /> pathway isoprenoid synthesis. Consequently, mutants <br />                                                                 plemented 100 mM mevalonate 100 mg/ml <br /> deficient genes dxr, gcpE lytB, respectively,                                                                 ampicillin. MEP taken E. coli, <br /> viable culture medium supplemented                                                                 [2-14C]MEP treated 2 U shrimp alkaline phos- <br /> mevalonate.20,21 Low-molecular-weight (LMW) extracts <br />                                                                 phatase (Roche Diagnostics, Mannheim, Germany) 37u <br /> prepared Ddxr DgcpE mutants signifi- <br />                                                                 30 min, resulting product, [2-14C]-methyl-D- <br /> cantly reduced capacity stimulate Vc9/Vd2 T cells, <br />                                                                 erythritol ([2-14C , added cultures compared parent E. coli strain,4 proving                                                                 concentration 50 mM (corresponding c. 17.1 kBq/ml). <br /> importance MEP pathway biosynthesis                                                                 Fosmidomycin, potent inhibitor Dxr enzyme,7 cd T-cell activator. striking contrast,                                                                 used 100 mM block endogenous biosynthesis DlytB bacteria, Vc9/Vd2 T cell-stimulating molecule <br />                                                                 MEP consequently ensure optimum incorpora- greatly accumulated. <br />                                                                 tion [2-14C metabolites produced MEP <br />                                                                 pathway. incubation 37u 6 hr, bacterial cells <br />                                                                 pelleted, resuspended 200 ml 5 mM Tris&#226;&#8364;&#8220;HCl, <br />               MATERIALS METHODS                             pH 7.5, lysed repeated freeze&#226;&#8364;&#8220;thaw cycles Bacteria plasmids                                           presence 2 mg lysozyme (Merck). Cell debris Bacterial strains E. coli DgcpE E. coli DlytB          pelleted supernatants loaded Microcon <br /> precise frame deletions gcpE lytB, respectively,      YM-3 filters (Millipore, Eschborn, Germany). flow- derived wild-type E. coli K-12 strain, DSM        lyophilized, resuspended 3 ml <span id='am-49' about='obo:IMR_0200357' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-50' property="rdfs:label" content="H2O" datatype="xsd:string"></span><span id='am-51' property="oboInOwl:hasDbXref" content="KEGG:C00001" datatype="xsd:string"></span><span id='am-52' property="oboInOwl:id" content="IMR:0200357" datatype="xsd:string"></span><span id='am-53' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>H2O</span>  498, ATCC 23716.20,21 mutant wild-type (WT)         analysed high performance layer chromato- <br /> strains harboured plasmid pSC-MVA synthetic              graphy silica gel plates (Kieselgel 60; Merck) developed operon express Saccharomyces cerevisiae ERG12                propanol : ethylacetate : H2O (6 : 1 : 3). Radioactive spots <br /> (mevalonate kinase), ERG8 (phosphomevalonate kinase)            visualized autoradiography exposure                                                                 4 weeks. ERG19 (mevalonate pyrophosphate decarboxylase).20 <br /> Bacteria grown Standard 1 medium (Merck, <br /> Darmstadt, Germany) presence 150 mg/ml                cd T-cell stimulation assays <br /> ampicillin (Sigma, Taufkirchen, Germany) 200 mM             Bacteria harvested fresh liquid cultures mevalonate; stock solution 1 M mevalonate              OD600 &lt;0.8 sonicated 1 : 10 volume prepared hydrolysing mevalonolactone (Fluka,                 phosphate-buffered saline (PBS). LMW fractions Taufkirchen, Germany) 1 M KOH 37u 30 min.           obtained using Centriprep 3-kDa filters (Millipore). <br />                                                                 Blood samples healthy donors kindly <br /> Synthesis 14C-labelled MEP                                   provided Institut fu&#194;&#168;r Klinische Immunologie enzymatic synthesis [2-14C]1-deoxy-D-xylulose            und Transfusionsmedizin (Klinikum der Justus-Liebig- <br /> 5-phosphate (DOXP), 0.8 mg pyruvate (Sigma), 1.4 mg          Universita&#194;&#168;t Giessen, Giessen, Germany). Peripheral blood [2-14C]pyruvate (585 MBq/mmol; NEN Life Science              mononuclear cells (PBMC) isolated heparinized <br /> Products, Zaventem, Belgium) 5.5 mg <span id='am-11' about='obo:IMR_0200474' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0002125'><span id='am-12' property="oboInOwl:hasDbXref" content="KEGG:C00095" datatype="xsd:string"></span><span id='am-13' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:id" content="IMR:0200474" datatype="xsd:string"></span><span id='am-15' property="rdfs:label" content="D-Fructose" datatype="xsd:string"></span>D-fructose</span>-          peripheral blood density centrifugation LSM <br /> 1,6-bisphosphate (Sigma) incubated 0.44 U rabbit      medium (ICN Biomedicals, Eschwege, Germany). PBMC <br /> aldolase     (D-fructose-1,6-bisphosphate-D-glyceraldehyde-     (2r105  seeded RPMI-1640 (200 ml) supple- <br /> 3-phosphate-lyase; Sigma), 22.4 U rabbit triose phosphate       mented 25 mM HEPES, 2 mM <span id='am-39' about='obo:IMR_0200448' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0001695 obo:IMR_0000001'><span id='am-40' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-41' property="oboInOwl:hasDbXref" content="KEGG:C00064" datatype="xsd:string"></span><span id='am-42' property="rdfs:label" content="L-Glutamine" datatype="xsd:string"></span><span id='am-43' property="oboInOwl:id" content="IMR:0200448" datatype="xsd:string"></span>L-glutamine</span>, 25 mg/ml <br />  <br />  <br /> #   2002 Blackwell Science  Immunology, 106, 200&#226;&#8364;&#8220;211 <br />  202                                                 M. Eberl et al. <br />  <br />  <br /> gentamycin  Life Technologies, Karlsruhe,            DgcpE #20, analysed electrospray ionization <br /> Germany) 10% human AB serum (Bayerisches Rotes            orthogonal-time flight mass spectrometry (ESI-o-ToF <br /> Kreuz, Augsburg, Germany). routine assays, recombi-       MS) (Mariner; PE Biosystems, Framingham, MA) <br /> nant human interleukin-2  2) (Life Technologies)       equipped nano-ESI-source (Protana, Odense, <br /> used 10 U/ml short-term cultures (18&#226;&#8364;&#8220;72 hr),       Denmark). Sample solutions (3 ml) filled gold- 100 U/ml longer culture periods. comparison        coated nanospray capillaries sprayed flow rates different growth factors, 2, 15            10&#226;&#8364;&#8220;30 nl/min. voltage nanospray needle set <br /> Promocell, Heidelberg, Germany), 2125 added         900 V; temperature heated transfer capillary concentration 0.1&#226;&#8364;&#8220;10 ng/ml. LMW preparations          200uC. Spectra taken negative <span id='am-21' about='obo:IMR_0001658' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-22' property="oboInOwl:hasDbXref" content="CHEBI:24870" datatype="xsd:string"></span><span id='am-23' property="obo:IAO_0000115" content="An atom that has either gained or lost electrons to acquire a chage; for example Na+ and Cl-." datatype="xsd:string"></span><span id='am-24' property="rdfs:label" content="ion" datatype="xsd:string"></span><span id='am-25' property="oboInOwl:id" content="IMR:0001658" datatype="xsd:string"></span><span id='am-26' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>ion</span> mode added dilutions 1 200 (corresponding         averaged 10 scans 3 seconds  Structural <br /> &lt;1.0r107 bacteria  1 5r106 (&lt;400 bacteria .   analysis MS-MS selected ions performed <br /> Cells incubated medium  cells stimulated         using quadruple ion trap MS (LCQ; Finnigan MAT, 10 mM IPP (Sigma), served negative positive       San Jose, CA) relative collision energy 20&#226;&#8364;&#8220;30%. <br /> controls, repectively. Cells harvested different <br /> time-points analysed cd T-cell activation cd      Statistical analysis <br /> T-cell outgrowth Epics XL flow cytometer sup-           Data expressed mean valuetstandard error ported Expo32 software (Beckman Coulter, Krefeld,        mean (SEM). Statistical analysis performed using <br /> Germany), using following Beckman Coulter                 tailed Student&#226;&#8364;&#8482;s t-test unequal variance, monoclonal antibodies (mAbs): CD3-PC5 (UCHT1),                differences considered statistically significant P-value <br /> Vc9-fluorescein isothiocyanate (FITC) (Immu360), Vd2-         &lt;0.05. R2 values calculated using Microsoft Excel <br /> FITC (Immu389), CD25-phycoerythrin (PE) (B1.49.9),            2000 software. <br /> CD69-PE (TP1.55.3), CD94-PE (HP-3B1), HLA-DR- <br /> PE (Immu357), appropriate isotype                                      RESULTS <br /> controls. Gates set total lymphocytes                                                               E. coli DlytB mutants accumulate metabolite CD3+ lymphocytes, results obtained 10 30 000 <br />                                                               derived methyl-D-erythritol <br /> gated events expressed percentage Vc9+ cells CD3+ lymphocytes day 6, CD69+ (day 1),        recent studies, demonstrated enzymes <br /> CD25+ (day 3), CD94+ (day 6), HLA-DR+ (day 6) cells        encoded E. coli genes gcpE lytB essential Vc9+ CD3+ lymphocytes. cytokine analysis,           isoprenoid synthesis MEP pathway.20,21 culture supernatants taken 18 72 hr,           final biochemical steps pathway remain tested tumour necrosis factor (TNF            unveiled, labelling experiments performed order <br /> interferon-c (IFN-c), respectively, using human OptEIA    gain detailed insight function LytB <br /> sets (Becton-Dickinson, Hamburg, Germany).                    GcpE proteins.  DlytB DgcpE mutants                                                               grown medium supplemented 14C-labelled  <br /> Chromatography mass spectrometry                          Separation corresponding LMW extracts  <br /> Cultures DgcpE DlytB mutants, respectively,       layer chromatography revealed DgcpE mutants, <br /> grown 100 ml Standard 1 medium OD600           [2-14C metabolized (Fig. 1). &lt;0.8. LMW extracts prepared described           contrast, DlytB mutant additional <br />  20 mM ammonium formiate, pH 8.0, used        spot indicating accumulation unknown metabolite <br /> instead PBS) passed Isolute C18 reverse-       reduced chromatographic mobility. Unfortunately, phase (RP) column (International Sorbent Technology,          amounts labelled material limited allow quan- <br /> Mid Glamorgan, UK). flow loaded          tification radioactivity liquid scintillation Source 15Q anion-exchange column (Amersham             characterization mass spectrometry (data shown). <br /> Pharmacia) fractionated using Waters HPLC device <br /> coupled PDA 996 photodiode array detector (Waters, <br />                                                               Disruption lytB gene leads &gt;100-fold <br /> Eschborn, Germany), scanning 1 spectrum/second                                                               accumulation cd T-cell stimulating molecule <br /> l210 500 nm 1.2-nm resolution. Buffers used   20 mM ammonium formiate, pH 8.0; B, 500 mM           previous work know compound derived <br /> ammonium formiate, pH 8.0; C, 1 M ammonium formiate;          MEP pathway represents natural activator chromatography performed flow rate          phosphoantigen-reactive human cd T cells.3,4  10 ml/min follows: wash, 30 min 100%  elution, linear    speculated metabolite accumulating DlytB <br /> gradient 100% 100% B 30 min; 10 min 100% C;      bacteria (Fig. 1) fact highly immunogenic <br /> equilibration, 10 min 100%  Fractions collected        substance.  cd T-cell stimulation assays, LMW tested standard cd T-cell activation assays     extracts prepared WT bacteria induced expansion dilution 1 400 000, using pools consisting      Vc9/Vd2 T cells dilutions 1 : 12 500, correspond- <br /> fractions  individual fractions pool   ing 1.6r105 bacteria (Fig. 2); accordance inducing upregulation CD69 expression 18 hr         previous observations,4 LMW extracts DgcpE tested dilution 1 400 000. active    mutants active WT E. coli. <br /> sample, DlytB #20, corresponding negative control,     striking contrast, DlytB mutants exhibited <br />  <br />  <br />                                                                       #   2002 Blackwell Science  Immunology, 106, 200&#226;&#8364;&#8220;211 <br />                                       potent cd T-cell activator DlytB E. coli                                                                                             203 <br />  <br />                                                                                            <br />                                                                                                                    80 <br />  <br />  <br />  <br />  <br />                                                                                       Vc9+ [% CD3+ lymphocytes] <br />                                                                                                                    60 <br />  <br />  <br />                                                                                                                    40 <br />  <br />  <br />                                                                                                                    20 <br />                <br />                                                                                                                     0 <br />                                                                                                                    1E+06          1E+05                1E +04        1E +03 <br />                                                                                                                                        Dilution factor <br />  <br />  <br />  <br />                                                                       (b) <br />                                                                                 103                                                                  103 <br />  <br />                                                                                 102                                             2.1%                 102                  10.1% <br />  <br />  <br />  <br />  <br />                                                                       CD3-PC5 <br />  <br />  <br />  <br />  <br />                                                                                                                                            CD3-PC5 <br />                                                                                 101                                                                  101 <br />  <br />                                                                                 100                                                                  100 <br />  <br />                                DgcpE     DlytB <br />                                                                                                                   100     101    102   103                  100      101   102    103 <br /> Figure 1.   layer chromatography analysis Escherichia                                                         Vc9-FITC                                  Vc9-FITC <br /> coli DgcpE DlytB grown presence [2-14C]2-C-methyl-D-              103                                                                  103 <br /> erythritol  . Low molecular weight preparations examined HPTLC silica gel plate, radioactive spots visualized             102                                             2.6%                 102                 55.8% autoradiography. <br />                                                                       CD3-PC5 <br />  <br />  <br />  <br />  <br />                                                                                                                                            CD3-PC5 <br />                                                                                 101                                                                  101 <br />  <br />  cd T-cell activity considerably                    100                                                                  100 <br /> WT bacteria; significant outgrowth Vc9/Vd2 T cells detected dilutions 1 : 312 500, cor-                                                          100     101    102   103                  100      101   102    103 <br /> responding 6.4r103 bacteria  relative increase                                                              Vc9-FITC                                  Vc9-FITC cd T cells detected did reflect true expansion population, substantial death ab T cells occurred            Figure 2. Disruption lytB gene increases cd T-cell <br /> (data shown), accordance similar                 stimulatory potential Escherichia coli.   Vc9+ T-cell outgrowth <br /> observations groups.2,17,26&#226;&#8364;&#8220;29                             presence bacterial extracts. Peripheral blood mononuclear <br />                                                                       cells (PBMC) incubated period 6 days medium <br />     investigated LMW extracts <br />                                                                        low molecular weight extracts prepared prepared DlytB bacteria, measuring immunological              wild-type E. coli (black triangles), DgcpE (open circles), parameters correlated cd T-cell activation phospho-           DlytB (open squares), different dilutions. Data shown represent <br /> antigens.  dilution 1 : 62 500, DlytB extract        mean values+standard error mean donors <br /> did stimulate proliferation cd T cells,          analysed. (b) Flow cytometry analysis. PBMC incubated induced upregulation activation markers CD25,                  medium  left panel), LMW extracts prepared <br /> CD69 HLA-DR, C-type lectin CD94                    WT E. coli  right panel), DgcpE  left panel), surface Vc9/Vd2 T cells, secretion TNF             DlytB  right panel), dilution 1 : 12 500. Panels shown <br />                                                                       representative data obtained blood donor. IFN-c PMBC (Fig. 3). activity present extracts WT DgcpE bacteria tested dilution.                                                             mutant significantly lower, equivalent &lt;0.8 mM. <br />     Using serial dilutions IPP standard, obtained            Strikingly, LMW extracts bacteria deficient lytB <br /> positive correlations antigen concentration               greater 100-fold active extracts cd T-cell activation, measured cd T-cell expansion                 WT bacteria, containing antigenic compound expression CD25 CD69 (Fig. 4). calibra-              potent &lt;450 mM IPP. <br /> tion curves enabled estimate activity bacterial extracts tested express IPP equivalents; <br />                                                                       cd T-cell stimulating molecule purified importantly, analyses performed gave similar <br />                                                                       anion-exchange chromatography <br /> levels (Table 1).  LMW extracts WT E. coli cd T-cell stimulatory potential comparable IPP                order characterize immunogenic molecule <br /> concentration &lt;3 mM, activity DgcpE             accumulating DlytB mutants, 3-kDa LMW filtrate <br />  <br />  <br /> #   2002 Blackwell Science  Immunology, 106, 200&#226;&#8364;&#8220;211 <br />  204                                                                                   M. Eberl et al. <br />  <br />                                                                        CD25                                                                             CD69 <br />  <br />  <br />  <br />  <br />                                                                                                 CD69+ (% Vc9+ CD3+ lymphocytes) <br />                    CD25+ (% Vc9+ CD3+ lymphocytes) <br />                                                      100                                                                            100 <br />  <br />                                                      80                                                                             80 <br />  <br />                                                      60                                                                             60 <br />  <br />                                                      40                                                                             40 <br />  <br />                                                      20                                                                             20 <br />  <br />                                                       0                                                                              0 <br />                                                            med   IPP    wt     gcpE   lytB                                                med    IPP      wt     gcpE   lytB <br />  <br />  <br />  <br />  <br />                                                                        CD94                                                                             HLA-DR <br />  <br />  <br />  <br />  <br />                                                                                                 HLA-DR+ (% Vc9+ CD3+ lymphocytes) <br />                    CD94+ (% Vc9+ CD3+ lymphocytes) <br />  <br />  <br />  <br />  <br />                                                      100                                                                            100 <br />  <br />                                                      80                                                                             80 <br />  <br />                                                      60                                                                             60 <br />  <br />                                                      40                                                                             40 <br />  <br />                                                      20                                                                             20 <br />  <br />                                                       0                                                                              0 <br />                                                            med   IPP    wt     gcpE   lytB                                                 med    IPP     wt     gcpE   lytB <br />  <br />  <br />  <br />  <br />                                                                        TNF                                                                             IFN-c <br />                                                      100                                                                            500 <br />  <br />                                                      80                                                                             400 <br />                          TNF (pg/ml) <br />  <br />  <br />  <br />  <br />                                                                                                        IFN-c (pg/ml) <br />  <br />  <br />  <br />  <br />                                                      60                                                                             300 <br />  <br />                                                      40                                                                             200 <br />  <br />                                                      20                                                                             100 <br />  <br />                                                       0                                                                              0 <br />                                                            med   IPP    wt     gcpE   lytB                                                 med    IPP     wt     gcpE   lytB <br />  <br />       Figure 3. Effect DlytB low molecular weight extract range immunological parameters. Peripheral blood <br />       mononuclear cells (PBMC) incubated medium  isopentenyl pyrophosphate (IPP) 2 mM, LMW <br />       extract prepared wild-type (WT) Escherichia coli, DgcpE, DlytB, dilution 1 : 62 500. Data represent results       donor, expression CD25 (day 3), CD69 (day 1), CD94 (day 6) human leucocyte antigen (HLA)-DR (day 6)       Vc9+ T cells, secretion tumour necrosis factor (TNF  (day 1) interferon-c (IFN-c) (day 3) PBMC. Note:       pattern shown typical number blood donors analysed (n=3&#226;&#8364;&#8220;6);  absolute levels CD94 HLA-DR <br />       expression, absolute amounts cytokines secreted, greater biological variation individuals       data cd T-cell expansion expression CD25 CD69.  donors changes CD94 HLA-DR <br />       expression presence serial dilutions phosphoantigens inconsistent despite good dose-dependent responses,       judged CD25 CD69 expression, making CD25 CD69 reproducible activation markers tested. <br />  passed C18 reversed-phase column                                                pools cd T-cell reactivity. sample obtained fractionated subsequently anion-exchange chromato-                                          DgcpE bacteria stimulated cd T cells background <br /> graphy, using ammonium formiate eluent. LMW                                              levels. contrast, peak bioactivity recovered preparation DgcpE bacteria subjected                                           pool consisting fractions 19&#226;&#8364;&#8220;22, samples protocol served control. Unexpectedly,                                     collected, flow column significant difference absorbance profiles                                       wash fractions, remained negative (Fig. 5). Testing DgcpE DlytB mutants, measured                                                  individual fractions positive pool showed 210 500 nm (Fig. 5, data shown).                                           cd T-cell-stimulating molecule eluted fraction  20, <br /> Consequently, fractions collected tested                                      ammonium formiate concentration &lt;250 mM. <br />  <br />  <br />                                                                                                                                       #   2002 Blackwell Science  Immunology, 106, 200&#226;&#8364;&#8220;211 <br />                                                potent cd T-cell activator DlytB E. coli                                          205 <br />  <br />                   10.0                                                 Table 1. Immunological activity extracts different strains <br />                                                                                             Escherichia coli&quot; <br />  <br />                                                                        Equivalent                    1.0                            R2 =0.997801         IPP (mM)               WT              DgcpE               DlytB <br />        IPP (&#194;&#181;M) <br />  <br />  <br />  <br />  <br />                                                                        Expt. 1{           4.04             0.69             462.58 <br />                                                                        Expt. 2{           2.54             0.85             475.11 <br />                    0.1 <br />                                                                        Expt. 31           2.66             0.79             394.64 <br />                                                                        MeantSEM           3.08t0.48        0.78t0.05*       444.11t25.00* <br />  <br />                    0.0                                                    &quot;Calibration curves obtained using serial dilutions                          0     20      40      60      80        100   isopentenyl pyrophosphate (IPP) standard (Fig. 4). Bioactivity                                 Vc9+ (% CD3+ lymphocytes)              bacterial extracts analysed expressed IPP equivalents                                                                        experiments performed. <br />                                                                           {Outgrowth Vc9+ CD3+ T cells, day 6 (n=3). <br />                   10.0                                                    {Upregulation CD25 Vc9+ CD3+ T cells, day 3 (n=3). <br />                                                                           1Upregulation CD69 Vc9+ CD3+ T cells, day 1 (n=3). <br />                                                                           *P&lt;0.05, using tailed Student&#226;&#8364;&#8482;s t-test unequal variance. <br />                                                                           SEM, standard error mean; WT, wild type. <br />  <br />                    1.0 <br />        IPP (&#194;&#181;M) <br />  <br />  <br />  <br />  <br />                                                 R2 =0.944496           derived DlytB bacteria, DlytB #20, cor- <br />                                                                        responding fraction DgcpE mutants, DgcpE #20.                    0.1                                                 negative ion spectrum DlytB #20, abundant <br />                                                                        peak m 261 [M-H]x; peaks m 381 <br />                                                                        [M+NaHPO4]x m 523 [2M-H]x correlated <br />                                                                        molecule (Fig. 6). signals detectable <br />                    0.0                                                 fraction DgcpE #20, prominent peak <br />                          0     20      40     60       80        100 <br />                                                                        m 277, common impurity peaks (e.g. m 216.9 <br />                              CD25+ (% Vc9+ CD3+ lymphocytes) <br />                                                                        m 1192.2) comparable intensities fraction <br />                                                                        DlytB #20; residual UV absorbance fractions <br />                   10.0                                                 DlytB #20 DgcpE #20 ascribed ion                                                                        m 1192.2 (data shown). Negative mode ion trap <br />                                R2 =0.998545                            MS/MS m 261 yielded ions m 243 (correspond- <br />                    1.0                                                 ing H2O loss) m 159 (corresponding pyro- <br />                                                                        phosphate anion, HP2Ox    6 ) (data shown). Subsequent <br />        IPP (&#194;&#181;M) <br />  <br />  <br />  <br />  <br />                                                                        large-scale purification cd T-cell activator                                                                        1-l culture E. coli DlytB mutants anion-exchange <br />                    0.1 <br />                                                                        chromatography, structural characterization                                                                        1 <br />                                                                          H, 13C 31P nuclear magnetic resonance spectros- <br />                                                                        copy nuclear Overhauser effect spectroscopy anal- <br />                    0.0                                                 ysis, (E )-4-hydroxy-3-methyl 2-enyl pyrophosphate <br />                          0     20      40     60       80        100 <br />                                                                        (HMB-PP) described 30 <br />                              CD69+ (% Vc9+ CD3+ lymphocytes) <br />  <br /> Figure 4. Dose&#226;&#8364;&#8220;response isopentenyl pyrophosphate (IPP). <br /> Peripheral blood mononuclear cells incubated medium          DlytB #20-driven cd T-cell activation does result  IPP different concentrations. data represent     secretion proinflammatory cytokines mean valuetSEM donors analysed, Vc9+ T-cell         presence 21 <br /> outgrowth, expression CD25 CD69 Vc9+ T cells. <br /> Trend lines R2 values calculated using Microsoft Excel        Apart reactivity small pyrophosphory- <br /> software.                                                              lated molecules, Vc9/Vd2 T cells depend cytokines                                                                        local microenvironment, fact bias read- <br /> Titration fraction  20 IPP standard gave              outs bioactivity assays. Consequently, investigated bioactivity corresponding &lt;2500 mM IPP (Table 2);                 influence different interleukins cd T-cell fraction  21 &lt;500 mM IPP bioactivity             response novel activator present fraction <br /> (data shown).                                                      DlytB #20. 2 15 clearly impor- <br />                                                                        tant growth factors known cd T cells,                                                                        synergize 12.26 21 novel cytokine Mass spectrometry analysis identifies molecule Mr 262 <br />                                                                        closely related 2 15, produced activated obtain structural information bioactive metabo-              CD4+ T cells CD19+ B cells CD14+ <br /> lite, ESI-MS analysis performed active fraction             monocytes.25  cytokines, 2, 15  <br />  <br /> #   2002 Blackwell Science  Immunology, 106, 200&#226;&#8364;&#8220;211 <br />  206                                                                                 M. Eberl et al. <br />  <br />                                                                                                                                   80 <br />  <br />  <br />  <br />  <br />                                                                                               CD69+ (% Vd2+ CD3+ lymphocytes) <br />                                                                                                                                                                                                          anion exchange column <br />  <br />                                                                                                                                   60 <br />  <br />  <br />                                                                                                                                   40 <br />  <br />  <br />                                                                                                                                   20 <br />  <br />  <br />                              0.8                                                                                                   0 <br />  <br />  <br />  <br />  <br />                                                                                                                                                                                                                        11-14 <br />  <br />                                                                                                                                                                                                                                     15-18 <br />  <br />                                                                                                                                                                                                                                                  19-22 <br />  <br />                                                                                                                                                                                                                                                               23-26 <br />  <br />                                                                                                                                                                                                                                                                            27-30 <br />  <br />                                                                                                                                                                                                                                                                                    31-35 <br />                                                                                                                                                                                                          wash <br />                                                                                                                                        medium <br />  <br />                                                                                                                                                  IPP <br />  <br />                                                                                                                                                        LMW <br />  <br />  <br />  <br />                                                                                                                                                                                                f/t <br />                                                                                                                                                              RP <br />                              0.6 <br />  <br />  <br />  <br />  <br />                                                                                                                                                              CD69+ (% Vd2+ CD3+ lymphocytes) <br />                                                                                                                                                                                                 80 <br />     Absorbance 280 nm <br />  <br />  <br />  <br />  <br />                                                                                                                                                                                                 60 <br />                              0.4 <br />                                                                                                                                                                                                 40 <br />  <br />  <br />                                                                                                                                                                                                 20 <br />  <br />                              0.2                                                                                                                                                                     0 <br />  <br />  <br />  <br />  <br />                                                                                                                                                                                                                                19 <br />  <br />                                                                                                                                                                                                                                             20 <br />  <br />                                                                                                                                                                                                                                                          21 <br />  <br />                                                                                                                                                                                                                                                                       22 <br />                                                                                                                                                                                                                 wash <br />                                0 <br />                                                                           19 <br />                                                                                20 <br />                                                                                     21 <br />                                                                                          22 <br />  <br />  <br />  <br />  <br />                            Figure 5. Fractionation bacterial extracts anion-exchange chromatography. DgcpE DlytB low molecular weight <br />                            (LMW) extracts, respectively, passed reverse phase (RP) column fractionated Source 15Q column, using <br />                            ammonium formiate gradient (20&#226;&#8364;&#8220;500 mM). Absorbance 280 nm shown solid line DlytB dashed line                            DgcpE. Fractions collected tested pools consisting  fractions 19 22 subsequently tested <br />                            individually ability upregulate CD69 expression Vd2+ T cells. Samples tested  medium control; isopentenyl <br />                            pyrophosphate (IPP) positive control, 10 mM; 3-kDa LMW filtrate, 1 50 000 (LMW) extract; LMW extract RP <br />                            column chromatography (=sample loaded Source 15Q column), 1 50 000 (RP); Source 15Q flow  1 50 000 <br />                            (f/t); Source 15Q wash fraction, 1 50 000; fractions 11&#226;&#8364;&#8220;35, pools individually, 1 400 000. Solid bars, DgcpE; hatched <br />                            bars, DlytB. <br />  <br />  <br />  21, costimulated expansion Vc9/Vd2 T cells                                                                            maximum 21 induced IFN-c levels lower CD3+ T cells presence fraction DlytB #20,                                                                       achieved presence 2 15. antigen cytokines significant <br /> proliferative effect (Fig. 7).  21 increased DlytB #20-driven upregulation CD25 CD69 Vc9/                                                                                                                                    DISCUSSION <br /> Vd2 T cells, similarly 2 15, effect                                                                    past years, Vc9/Vd2 T cells shown CD25 CD69 expression absence antigenic                                                                         react pathogenic bacteria, Brucella, <br /> stimulation barely detectable, contrast                                                                     Coxiella, Ehrlichia, E. coli, Francisella, Legionella, Listeria, <br /> cytokines tested. Addition 21 PBMC cultures                                                                            Mycobacterium, Pseudomonas, Salmonella Yersinia, enhanced 2- 15-induced upregulation CD69                                                                        protozoan parasites Plasmodium expression, presence absence antigenic                                                                        Toxoplasma.12,31,32 bacteria lacking stimulation; additive effect CD25 expression cd                                                                      alternative MEP pathway isoprenoid synthesis, T-cell proliferation pronounced (data shown).                                                                      Staphylococcus Streptococcus, capable 2 15 costimulated DlytB #20-induced                                                                         stimulating Vc9/Vd2 T cells superantigen recognition <br /> synthesis TNF IFN-c PBMC, 21 did                                                                            sites,33,34 recent studies established general link enhance DlytB #20-driven TNF production,                                                                              Vc9/Vd2 T-cell reactivity35 presence  <br />  <br />                                                                                                                                         #       2002 Blackwell Science  Immunology, 106, 200&#226;&#8364;&#8220;211 <br />                                                     potent cd T-cell activator DlytB E. coli                                                                                  207 <br />  <br />  <br /> MEP pathway.3,4 Accordingly, current data                                                                   HLA-DR,36 killer inhibitory receptor, clear LytB enzyme21 plays crucial role                                                               CD94,37 surface Vc9/Vd2 T cells, proliferation <br /> metabolism natural Vc9/Vd2 TCR ligand. Stimula-                                                                     expansion Vc9/Vd2 T cells,4 secretion tion human PBMC minute quantities DlytB                                                                         proinflammatory cytokines IFN-c TNF 27,38,39 <br /> LMW preparations led drastic upregulation                                                                          Recently, molecule Mr 262 (TUBag1) identified <br /> known T-cell activation markers CD25,26 CD6926                                                                         Mycobacterium fortuitum. Data ion-trap ESI-MS <br />                                                                                                                            comparative photodiode array absorption analysis <br />                                                                                                                            TUBag1, NMR spectroscopy signals       Table 2. Immunological activity fraction DlytB #20*                                                               obtained using corresponding c-<span id='am-72' about='obo:IMR_0200199' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-73' property="rdfs:label" content="UTP" datatype="xsd:string"></span><span id='am-74' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-75' property="oboInOwl:hasDbXref" content="KEGG:C00075" datatype="xsd:string"></span><span id='am-76' property="oboInOwl:id" content="IMR:0200199" datatype="xsd:string"></span>UTP</span> c-TTP <br />                                                                                                                            phosphodiesters, TUBag3 TUBag4, suggested                                  CD69 expression                                Bioactivity <br /> Dilution factor                 (% Vc9+ CD3+){                                  (mM IPP){ <br />                                                                                                                            mycobacterial cd T-cell activator FBPP.13,16,17                                                                                                                            potent natural Vc9/Vd2 T-cell stimulator <br /> Medium control                          29.8t8.4                             &#226;&#8364;&#8220;                                             identified <span id='am-10' about='oboInOwl:date' typeof='owl:Thing'>date</span>, compound active low nM <br /> 6.25r107                                29.9t12.4                            &#226;&#8364;&#8220;                                             range, natural synthetic substances <br /> 1.25r107                                35.1t7.0                             3759.5                                         IPP prenyl pyrophosphates, alkyl- <br /> 2.5r106                                 40.4t1.4                             1823.8 <br />                                                                                                                            phosphates, alkylamines, aminobisphosphonates) 5.0r105                                 52.2t0.2                             2592.5 <br /> 1.0r105                                 63.0t1.3                             3104.2 <br />                                                                                                                            bioactivities 1 100 mM.13,15,28,29,40&#226;&#8364;&#8220; 42 2.0r104                                 66.2t0.6                             1065.9                                         synthetic FBPP derivatives halohydrin <br /> MeantSEM1                               &#226;&#8364;&#8220;                                    2469.2t472.7                                  pyrophosphates bioactivities similar   <br />                                                                                                                            naturally occurring cd T-cell activator,     calibration curve obtained using serial dilutions                                                          described.43&#226;&#8364;&#8220; 46  connection FBPP isopentenyl pyrophosphate (IPP) standard, ranging 80 nM <br />                                                                                                                            MEP pathway isoprenoid synthesis 10 mM yielding formula  R2=0.99): Bioactivity <br />                           . <br /> (mM IPP)=0.000869re0 167r(CD69 expression level).                                                                          deduced indirectly close structural similarity <br />    {Upregulation CD69 expression monitored incubation                                                         FBPP IPP.17 mass 262 atomic units peripheral blood mononuclear cells 18 hr presence serial                                                  fragments m 243 m 159, dilutions fraction DlytB #20 (n=3). <br />                                                                                                                            present study, accordance <span id='am-1' about='obo:IMR_0000947' typeof='owl:Thing obo:IMR_0000001'><span id='am-2' property="oboInOwl:id" content="IMR:0000947" datatype="xsd:string"></span><span id='am-3' property="rdfs:label" content="chemical" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>chemical</span> structure <br />    {Bioactivity fraction DlytB #20 calculated dilution <br /> using formula: BioactivityDlytB #20 (mM IPP)=(1/1000r[bioactivity                                                      FBPP;17  related molecules 3,4-epoxy- <br /> (mM IPP)rdilution factor]).                                                                                                3-methyl-1-butyl pyrophosphate (EpoxPP),    1Mean bioactivity dilutions tested resulted                                                       identical fragmentation patterns,44 making upregulation CD69 expression background value.                                                                                                                            MS-based approach insufficient support proposed <br /> analogous experiment measuring cd T-cell expansion 6 days <br /> resulted bioactivity value 2487.6t911.4 mM IPP.                                                                    structure.45  recent 1H, 13C 31P NMR spectros- <br />    SEM, standard error mean.                                                                                        copy studies purified substance identified                                                                  277.0 <br />  <br />  <br />  <br />  <br />                           DgcpE <br />  <br />                                         100 <br />                           % Intensity <br />  <br />  <br />  <br />  <br />                                          50 <br />                                                   216.9 <br />  <br />                                                                      299.0 <br />  <br />  <br />                                                                               396.9 <br />                                                  133.0 <br />  <br />  <br />  <br />  <br />                                                                                                                                                                      1192.2 <br />                                                                                                                   554.9 <br />                                                 179.0 <br />                                                  97.0 <br />  <br />  <br />  <br />                                                 244.1 <br />  <br />  <br />                                                                              374.9 <br />  <br />  <br />  <br />  <br />                                                                                                                                           771.2 <br />                                                                                                                                   673.2 <br />  <br />  <br />  <br />  <br />                                                                                                                                                       854.9 <br />  <br />  <br />  <br />  <br />                                             0 <br />                                                                   300                                   550                                800                1050            m                                                                 [M-H]&#226;&#8364;&#8220; <br />                                                                 261.0 <br />  <br />  <br />  <br />  <br />                           DlytB <br />  <br />                                         100 <br />                                                                               380.9 [M+NaHPO4]&#226;&#8364;&#8220; <br />                           % Intensity <br />  <br />  <br />  <br />  <br />                                                                                                   523.0 [2M-H]&#226;&#8364;&#8220; <br />  <br />  <br />  <br />  <br />                                          50 <br />                                                                  277.0 <br />                                                         216.9 <br />                                                        158.9 <br />  <br />  <br />  <br />  <br />                                                                                                                                                                      1192.2 <br />                                                 97.0 <br />  <br />  <br />  <br />  <br />                                                                                                                                               806.9 <br />                                                                                                                           642.9 <br />  <br />  <br />  <br />  <br />                                             0 <br />                                                                   300                                   550                                800                1050            m  <br />         Figure 6. Negative mode electrospray ionization-mass spectrometry (ESI-MS) analysis fractions DgcpE #20 DlytB #20. <br />  <br />  <br /> #   2002 Blackwell Science  Immunology, 106, 200&#226;&#8364;&#8220;211 <br />  208                                                                        M. Eberl et al. <br />  <br />  <br />  <br />  <br />       CD69+ (% Vc9+ CD3+ lymphocytes) <br />                                         100                              100                                100 <br />  <br />                                          80                               80                                 80 <br />  <br />                                          60                               60                                 60 <br />  <br />                                          40                               40                                 40 <br />  <br />                                          20                               20                                 20 <br />  <br />                                           0                                0                                  0 <br />                                                0   0.1     1.0    10.0          0   0.1    1.0       10.0          0   0.1    1.0   10.0 <br />       CD25+ (% Vc9+ CD3+ lymphocytes) <br />  <br />  <br />  <br />  <br />                                         100                              100                                100 <br />  <br />                                          80                               80                                 80 <br />  <br />                                          60                               60                                 60 <br />  <br />                                          40                               40                                 40 <br />  <br />                                          20                               20                                 20 <br />  <br />                                           0                                0                                  0 <br />                                                0   0.1     1.0    10.0          0   0.1    1.0       10.0          0   0.1    1.0   10.0 <br />  <br />  <br />                                          30                               30                                 30 <br />       Vc9+ (% CD3+ lymphocytes) <br />  <br />  <br />  <br />  <br />                                          20                               20                                 20 <br />  <br />  <br />  <br />                                          10                               10                                 10 <br />  <br />  <br />  <br />                                           0                                0                                  0 <br />                                                0   0.1     1.0    10.0          0   0.1    1.0       10.0          0   0.1    1.0   10.0 <br />  <br />  <br />                                         800                              800                                 800 <br />  <br />  <br />                                         600                              600                                 600 <br />             TNF (pg/ml) <br />  <br />  <br />  <br />  <br />                                         400                              400                                 400 <br />  <br />  <br />                                         200                              200                                 200 <br />  <br />  <br />                                           0                                0                                  0 <br />                                                0   0.1     1.0    10.0          0   0.1    1.0       10.0          0   0.1    1.0   10.0 <br />  <br />  <br />                                         2500                             2500                               2500 <br />  <br />                                         2000                             2000                               2000 <br />             IFN-c (pg/ml) <br />  <br />  <br />  <br />  <br />                                         1500                             1500                               1500 <br />  <br />                                         1000                             1000                               1000 <br />  <br />                                          500                              500                                500 <br />  <br />                                           0                                0                                  0 <br />                                                0    0.1    1.0    10.0          0    0.1     1.0 10.0              0    0.1     1.0 10.0 <br />                                                    2 (ng/ml)                     15 (ng/ml)                      21 (ng/ml) <br />  <br />  <br />  <br />  <br />                                                                                                  #   2002 Blackwell Science  Immunology, 106, 200&#226;&#8364;&#8220;211 <br />                                            potent cd T-cell activator DlytB E. coli                                                  209 <br />  <br />  <br /> cd TCR ligand accumulating E. coli DlytB mutants                       eluted anion-exchange column HMB-PP, novel compound derived MEP                          conditions m 261 compound; correspon- <br /> pathway &lt;104 times potent activating Vc9/                 dence chromatographical behaviour result <br /> Vd2 T cells IPP.30 contrast FBPP, chemical                 close chemical similarity metabolites <br /> structure HMB-PP accordance incorporation                   MEP pathway. presence pyrophosphate <br /> studies using deuterium-labelled isotopomers,18                    group m 277 molecule confirmed ion trap <br /> insinuates elegant mechanism unclear                 MS/MS (U. Bahr M. Hintz, unpublished).  <br /> biosynthetic reaction sequence leading MEcPP IPP                  ings suggest E. coli DgcpE overproduc- <br /> (Fig. 8).  present know                  tion MEcPP serve putative substrate <br /> Vc9/Vd2 TCR ligand actual substrate LytB                    GcpE enzyme catalysing synthesis natural <br /> merely represents product MEP pathway,                      cd TCR ligand, precursor.47 conclusion cor- <br /> utilizing intermediate produced GcpE                     roborated recent data indicating MEcPP itself does unidentified enzyme downstream GcpE).                          display cd T-cell activity.48 <br /> recently Hecht et al. detected HMB-PP bacteria                        addition molecular characterization overexpressing gcpE gene,47 supporting                   cd T-cell activator, identified 21 potent <br /> conclusions.30                                                            costimulator human phosphoantigen-reactive Vc9/Vd2 <br />     Finally, important note E. coli DgcpE                   T cells. confirms expansion activated cd T cells <br /> mutants accumulate metabolite derived                     depends additional growth factors derive MEP pathway, detectable mass m 277                     bystander CD4+ T cells antigen-specific <br />                                                                           immune response pathogen, 2, 4                                                                           7, cells innate immune early <br />                                 DOXP <br />                                                                           stages infection CD4+ T cells                                                                           recruited, like 12 15.26 synergism                                         Dxr                               21 2 15 accordance previous <br />                                                                           findings showing combinations 21 2 <br />                                  MEP                                      15 additive effect lytic function                                         YgbP                              human natural killer cells;  21 potentiates <br />                                         YchB                              costimulation murine T-cell proliferation 2 <br />                                         YgbB                              15.25,49 biological implication seemingly <br />                                                                           redundant utilization 21 Vc9/Vd2 T-cell <br />                                 MEcPP <br />                                                                           costimulator remains elucidated, 2                                         GcpE                              21 produced activated CD4+ T cells,                                                                           signalling interleukins, 2, 15 21, <br />                                HMB-PP <br />                                                                           respective receptors involves activation STAT1, <br />                           (cd T cell activator)                           STAT3 STAT5, JAK1 JAK3.50,51                                                                           respect, intriguing 21 similar effects                                         LytB                              2 15 DlytB #20-driven cd T-cell pro- <br />                                                                           liferation CD25 CD69 surface expression,                                   IPP                                     far active stimulating DlytB #20-induced <br />                                                                           secretion IFN-c TNF PBMC. findings <br /> Figure 8. Proposed scheme final biosynthetic reactions <br />                                                                           demonstrate production proinflammatory 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway Escherichia coli. Initially, 1-deoxy-D-xylulose 5-phosphate (DOXP)        cytokines, considered key function converted MEP DOXP reductoisomerase (Dxr).                     Vc9/Vd2 T cells widely used read bio- <br /> Subsequently, enzymes YgbP, YchB YgbB catalyse                activity assays,27,38,39 necessarily associated transformation MEP 2-C-methyl-D-erythritol 2,4-cyclo-             proliferating Vc9/Vd2 T cells. immunology 21 <br /> pyrophosphate (MEcPP), molecular mass (Mr) 278.                 costimulated phosphoantigen-reactive Vc9/Vd2 T cells GcpE involved step(s) using MEcPP substrate          worth attention. <br /> produce cd T-cell activator, (E )-4-hydroxy-3-methyl 2-enyl           Taken  demonstrated pyrophos- <br /> pyrophosphate (HMB-PP) Mr 262, LytB mediates <br />                                                                           phorylated molecule Mr 262 accounts strong subsequent reaction leading IPP. <br />                                                                           immunogenicity mutant E. coli strain deficient lytB. <br />  <br />  <br />         Figure 7. Dependence cd T-cell activity costimulation interleukin  -2, 15 21. Peripheral blood <br />         mononuclear cells incubated medium (open circles), DlytB #20 dilution 1 100 000, <br />         corresponding bioactivity equivalent 25 mM isopentenyl pyrophosphate (IPP) (solid circles), presence different <br />         concentrations recombinant cytokines. Data shown represent mean value+SEM expression CD69 CD25 <br />         Vc9+ CD3+ T cells, outgrowth Vc9+ T cells CD3+ T cells, secretion interferon-c (IFN-c)         tumour necrosis factor (TNF   n=6 n=3 IFN-c). *P&lt;0.05 compared corresponding medium <br />         controls, using tailed Student&#226;&#8364;&#8482;s t-test paired data. <br />  <br />  <br /> #   2002 Blackwell Science  Immunology, 106, 200&#226;&#8364;&#8220;211 <br />  210                                                          M. Eberl et al. <br />  <br />  increasing evidence Vc9/Vd2 T cells                    11 Eisenreich W, Rohdich F, Bacher  Deoxyxylulose phosphate <br /> contribute immune response                      pathway terpenoids. Trends Plant Sci 2001; 6:78&#226;&#8364;&#8220;84. harmful pathogens infecting humans, unexpected                 12 Sicard H, Fournie&#194;&#180; JJ. Metabolic routes targets accessibility natural Vc9/Vd2 TCR ligand large                   immunological discrimination host parasite. Infect <br />                                                                            Immun 2000; 68:4375&#226;&#8364;&#8220;7. <br /> quantities, identification 21 potent growth <br />                                                                         13 Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, <br /> factor, aid understanding unconven- <br />                                                                            Bonneville M, Fournie&#194;&#180; JJ. Stimulation human cd T cells tional function Vc9/Vd2 T cells diseases                     nonpeptidic mycobacterial ligands. Science 1994; 264:267&#226;&#8364;&#8220;70. <br /> tuberculosis, tularemia, malaria, Crohn&#226;&#8364;&#8482;s disease.52&#226;&#8364;&#8220;55              14 Tanaka Y, Sano S, Nieves E et al. Nonpeptide ligands fact presence 21, DlytB #20-reactive                 human cd T cells. Proc Natl Acad Sci USA 1994; 91:8175&#226;&#8364;&#8220;9. <br /> Vc9/Vd2 T-cells proliferate secreting significant               15 Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, <br /> levels proinflammatory cytokines consider-                    Bloom BR. Natural synthetic non-peptide antigens <br /> able relevance immunotherapeutic approaches                   recognized human cd T cells. Nature 1995; 375:155&#226;&#8364;&#8220;8. <br /> infections.                                                             16 Poquet Y, Constant P, Halary F et al. novel <span id='am-54' about='obo:IMR_0001349' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001698'><span id='am-55' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-56' property="oboInOwl:hasExactSynonym" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-57' property="rdfs:label" content="nucleotide" datatype="xsd:string"></span><span id='am-58' property="oboInOwl:id" content="IMR:0001349" datatype="xsd:string"></span><span id='am-59' property="oboInOwl:hasDbXref" content="CHEBI:25608" datatype="xsd:string"></span><span id='am-60' property="obo:IAO_0000115" content="A nucleotide consists of a nitrogen-containing base, a five-carbon sugar, and one or more phosphate groups. Nucleotides can carry chemical energy (e.g. ATP), form coenzymes (e.g. CoA), be used as specific signaling molecules (e.g. cAMP) in the cell. Nucleotides are the subunits of the nucleic acids. " datatype="xsd:string"></span><span id='am-61' property="rdfs:label" content="nucleoside phosphate" datatype="xsd:string"></span>nucleotide</span>- <br />                                                                            containing antigen human blood cd T lymphocytes. Eur <br />                                                                            J Immunol 1996; 26:2344 &#226;&#8364;&#8220;9. <br />                    ACKNOWLEDGMENTS                                      17 Belmant C, Espinosa E, Poupot R, Peyrat MA, Guiraud M, study supported Bundesministerium fu&#194;&#168;r Bildung             Poquet Y, Bonneville M, Fournie&#194;&#180; JJ. 3-Formyl-1-butyl <br /> und Forschung (BioChance 0312588), studentship               pyrophosphate: novel mycobacterial metabolite-activating Deutsche Forschungsgemeinschaft  K.K). gratefully              human cd T cells. J Biol Chem 1999; 274:32079&#226;&#8364;&#8220;84. <br /> acknowledge Rosel Engel, Christian Haug, Dajana Henschker,              18 Charon L, Hoeffler JF, Pale-Grosdemange C, Lois LM, <br /> Ursula Jost, Irina Steinbrecher, Stefanie Wagner excellent         Campos N, Boronat  Rohmer M. Deuterium-labelled <br /> technical assistance; Erhard Dreiseidler, Claus Weidemeyer,            isotopomers 2-C-methyl-D-erythritol tools elucida- Oliver Wolf helpful discussions.                                   tion 2-C-methyl-D-erythritol 4-phosphate pathway                                                                            isoprenoid biosynthesis. Biochem J 2000; 346:737&#226;&#8364;&#8220; 42. <br />                                                                         19 Takahashi S, Kuzuyama T, Watanabe H, Seto H. 1-deoxy- <br />                          REFERENCES                                        D-xylulose 5-phosphate reductoisomerase catalyzing forma- <br />                                                                            tion 2-C-methyl-D-erythritol 4-phosphate alternative <br />  1 Goerlich R, Hacker G, Pfeffer K, Heeg K, Wagner H. <br />                                                                            nonmevalonate pathway terpenoid biosynthesis. Proc Natl <br />    Plasmodium falciparum merozoites primarily stimulate                                                                            Acad Sci USA 1998; 95:9879&#226;&#8364;&#8220;84. <br />    Vc9 subset human c/d T cells. Eur J Immunol 1991; <br />                                                                         20 Altincicek B, Kollas AK, Sanderbrand S, Wiesner J, Hintz M, <br />    21:2613&#226;&#8364;&#8220;6. <br />                                                                            Beck E, Jomaa H. GcpE involved 2-C-methyl-D- <br />  2 Kabelitz D, Bender  Schondelmaier S, Schoel B, <br />                                                                            erythritol 4-phosphate pathway isoprenoid biosynthesis    Kaufmann SH. large fraction human peripheral blood <br />                                                                            Escherichia coli. J Bacteriol 2001; 183:2411&#226;&#8364;&#8220;6. <br />    c/d+ T cells activated Mycobacterium tuberculosis                                                                         21 Altincicek B, Kollas AK, Eberl M, Wiesner J, Sanderbrand S, <br />    65-kDa heat shock protein. J Exp Med 1990; 171:667&#226;&#8364;&#8220;75. <br />                                                                            Hintz M, Beck E, Jomaa H. LytB, novel gene 2-C- <br />  3 Jomaa H, Feurle J, Luhs K, Kunzmann V, Tony HP, <br />    Herderich M, Wilhelm M. Vc9/Vd2 T cell activation induced               methyl-D-erythritol 4-phosphate pathway isoprenoid <br />    bacterial low molecular mass compounds depends                    biosynthesis Escherichia coli. FEBS Lett 2001; 499:37&#226;&#8364;&#8220; 40. <br />    1-deoxy-D-xylulose 5-phosphate pathway isoprenoid             22 Cunningham FX Jr, Lafond TP, Gantt E. Evidence role    biosynthesis. FEMS Immunol Med Microbiol 1999; 25:371&#226;&#8364;&#8220;8.                LytB nonmevalonate pathway isoprenoid biosynthesis. <br />  4 Altincicek B, Moll J, Campos N et al. Human cd T cells              J Bacteriol 2000; 182:5841&#226;&#8364;&#8220;8. <br />    activated intermediates 2-C-methyl-D-erythritol            23 Campos N, Rodr&#196;&#177;&#194;&#180;guez-Concepcio&#194;&#180;n M, Seemann M, Rohmer M, <br />    4-phosphate pathway isoprenoid biosynthesis. J Immunol               Boronat  Identification gcpE novel gene 2-C- <br />    2001; 166:3655&#226;&#8364;&#8220;8.                                                       methyl-D-erythritol 4-phosphate pathway isoprenoid bio- <br />  5 Rohmer M, Knani M, Simonin P, Sutter B, Sahm H. Isoprenoid              synthesis Escherichia coli. FEBS Lett 2001; 488:170 &#226;&#8364;&#8220;3. <br />    biosynthesis bacteria: novel pathway early              24 Altincicek B, Hintz M, Sanderbrand S, Wiesner J, Beck E, <br />    steps leading <span id='am-27' about='obo:IMR_0200287' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-28' property="oboInOwl:id" content="IMR:0200287" datatype="xsd:string"></span><span id='am-29' property="rdfs:label" content="Isopentenyl diphosphate" datatype="xsd:string"></span><span id='am-30' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-31' property="oboInOwl:hasDbXref" content="KEGG:C00129" datatype="xsd:string"></span>isopentenyl diphosphate</span>. Biochem J 1993;               Jomaa H. Tools discovery inhibitors 1-deoxy-D- <br />    295:517&#226;&#8364;&#8220;24.                                                             xylulose 5-phosphate (DXP) synthase DXP reducto- <br />  6 Rosa Putra S, Disch  Bravo JM, Rohmer M. Distribution              isomerase: approach enzymes pathogenic <br />    mevalonate glyceraldehyde 3-phosphate/pyruvate routes               bacterium Pseudomonas aeruginosa. FEMS Microbiol Lett <br />    isoprenoid biosynthesis Gram-negative bacteria          2000; 190:329&#226;&#8364;&#8220;33. <br />    mycobacteria. FEMS Microbiol Lett 1998; 164:169&#226;&#8364;&#8220;75.                  25 Parrish-Novak J, Dillon SR, Nelson et al. Interleukin 21  7 Jomaa H, Wiesner J, Sanderbrand S et al. Inhibitors                  receptor involved NK cell expansion regulation <br />    nonmevalonate pathway isoprenoid biosynthesis                 lymphocyte function. Nature 2001; 408:57&#226;&#8364;&#8220;63. <br />    antimalarial drugs. Science 1999; 285:1573&#226;&#8364;&#8220;6.                        26 Wesch D, Marx S, Kabelitz D. Comparative analysis ab <br />  8 Rohmer M. discovery mevalonate-independent path-               cd T cell activation Mycobacterium tuberculosis    way isoprenoid synthesis bacteria, algae higher plants.      isopentenyl pyrophosphate. Eur J Immunol 1997; 27:952&#226;&#8364;&#8220;6. <br />    Nat Prod Rep 1999; 16:565&#226;&#8364;&#8220;74.                                        27 Garc&#196;&#177; VE, Sieling PA, Gong J et al. Single-cell cytokine <br />  9 Lange BM, Rujan T, Martin W, Croteau R. Isoprenoid                      analysis cd T cell responses nonpeptide mycobacterial <br />    biosynthesis: evolution ancient distinct pathways        antigens. J Immunol 1997; 159:1328&#226;&#8364;&#8220;35. <br />    genomes. Proc Natl Acad Sci USA 2000; 97:13172&#226;&#8364;&#8220;7.             28 Bukowski JF, Morita CT, Brenner MB. Human cd T cells <br /> 10 Boucher Y, Doolittle WF. role lateral gene transfer       recognize alkylamines derived microbes, edible plants, <br />    evolution isoprenoid biosynthesis pathways. Mol Microbiol            tea: implications innate immunity. Immunity 1999; <br />    2000; 37:703&#226;&#8364;&#8220;16.                                                        11:57&#226;&#8364;&#8220;65. <br />  <br />  <br />                                                                                 #   2002 Blackwell Science  Immunology, 106, 200&#226;&#8364;&#8220;211 <br />                                       potent cd T-cell activator DlytB E. coli                                                 211 <br />  <br /> 29 Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP,              42 Espinosa E, Belmant C, Sicard H, Poupot R, Bonneville M, <br />    Wilhelm M. Stimulation cd T cells aminobisphosphonates          Fournie&#194;&#180; JJ. Y2K+1 state art non-peptide phospho- <br />    induction antiplasma cell activity multiple myeloma.        antigens, novel category immunostimulatory molecules. <br />    Blood 2000; 96:384 &#226;&#8364;&#8220;92.                                               Microbes Infect 2001; 3:645&#226;&#8364;&#8220;54. <br /> 30 Hintz M, Reichenberg  Altincicek B et al. Identification      43 Belmant C, Espinosa E, Halary F et al. chemical basis    (E )-4-hydroxy-3-methyl 2-enyl pyrophosphate major           selective recognition nonpeptide antigens human cd T cells. <br />    activator human cd T cells Escherichia coli. FEBS Lett         FASEB J 2000; 14:1669&#226;&#8364;&#8220;70. <br />    2001; 509:317&#226;&#8364;&#8220;22.                                                  44 Pont F, Luciani B, Belmant C, Fournie&#194;&#180; JJ. Characterization <br /> 31 Kaufmann SH. c/d unconventional T lymphocytes:              phosphoantigens high-performance anion-exchange <br />     Proc Natl Acad Sci USA          chromatography-electrospray ionization ion trap mass <br />    1996; 93:2272&#226;&#8364;&#8220;9.                                                      spectrometry nanoelectrospray ionization ion trap mass <br /> 32 Kabelitz D, Glatzel  Wesch D. Antigen recognition                spectrometry. Anal Chem 2001; 73:3562&#226;&#8364;&#8220;9. <br />    human cd T lymphocytes. Int Arch Allergy Immunol 2000;             45 Feurle J, Espinosa E, Eckstein S et al. E. coli produces <br />    122:1&#226;&#8364;&#8220;7.                                                              phosphoantigens activating human cd T cells. J Biol Chem 2002; <br /> 33 Munk  Gatrill AJ, Kaufmann SH. Target cell lysis 2          277:148&#226;&#8364;&#8220;54. <br />    secretion c/d T lymphocytes activation bacteria.     46 Espinosa E, Belmant C, Pont F et al. Chemical synthesis <br />    J Immunol 1990; 145:2434 &#226;&#8364;&#8220;9.                                          biological activity bromohydrin pyrophosphate, 34 Morita CT, Li H, Lamphear JG, Rich RR, Fraser JD,                     potent stimulator human cd T cells. J Biol Chem 2001; <br />    Mariuzza RA, Lee HK. Superantigen recognition cd <br />                                                                          276:18337&#226;&#8364;&#8220; 44. <br />    T cells: SEA recognition site human Vc2 T cell receptors. <br />                                                                       47 Hecht S, Eisenreich W, Adam P et al. Studies    Immunity 2001; 14:331&#226;&#8364;&#8220; 44. <br />                                                                          nonmevalonate pathway terpenes: role GcpE <br /> 35 Allison TJ, Winter CC, Fournie&#194;&#180; JJ, Bonneville M, Garboczi DN. <br />                                                                          (IspG) protein. Proc Natl Acad Sci USA 2001; 98:14837&#226;&#8364;&#8220; 42. <br />    Structure human cd T-cell antigen receptor. Nature 2001; <br />                                                                       48 Potapov VD, Biketov SF, Demina GR, Lysak EI, Titareva GM, <br />    411:820 &#226;&#8364;&#8220; 4. <br />                                                                          Bakhteeva IV, Ostrovsky DN. Immunomodulatory properties <br /> 36 Borsellino G, Poccia F, Placido R et al. Phenotypic                                                                          2-C-methyl-D-erythritol 2,4-cyclopyrophosphate    functional properties cd T cells patients Guillain <br />                                                                          search new derivatives. Appl Biochem Microbiol 2001; <br />    Barre&#194;&#180; syndrome. J Neuroimmunol 2000; 102:199&#226;&#8364;&#8220;207. <br /> 37 Boullier S, Poquet Y, Halary F, Bonneville M, Fournie JJ,             37:238&#226;&#8364;&#8220; 41. <br />    Gougeon ML. Phosphoantigen activation induces surface              49 Vo&#195;&#376;henrich CA, di Santo JP. Cytokines: 21 joins    translocation intracellular CD94/NKG2A class receptor            cc-dependent network? Curr Biol 2001; 11:R175&#226;&#8364;&#8220;7. <br />    CD94x peripheral Vc9Vd2 T cells CD94x thymic         50 Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ. <br />    mature cd T cell clones. Eur J Immunol 1998; 28:3399&#226;&#8364;&#8220; 410.         Cloning type cytokine receptor related 2 <br /> 38 Sireci G, Champagne E, Fournie&#194;&#180; JJ, Dieli F, Salerno  Patterns      receptor beta chain. Proc Natl Acad Sci USA 2000; <br />    phosphoantigen stimulation human Vc9/Vd2 T cell clones          97:11439&#226;&#8364;&#8220; 44. <br />    include Th0 cytokines. Hum Immunol 1997; 58:70 &#226;&#8364;&#8220;82.                51 Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D, <br /> 39 Lafont V, Liautard J, Liautard JP, Favero J. Production            Sugamura K. Th <br /> </body></html>